middle.news
Bluechiip Eyes 2025 Growth Amid Strategic Review and BioLife Partnership
6:46pm on Sunday 1st of June, 2025 AEST
•
Healthcare
Read Story
Bluechiip Eyes 2025 Growth Amid Strategic Review and BioLife Partnership
6:46pm on Sunday 1st of June, 2025 AEST
Key Points
Shares suspended pending 2024 audited accounts and Annual Report
Strategic Review ongoing with focus on partnerships, refinancing, and potential sale
BioLife deal announced in December 2024 seen as key revenue driver
Established solid customer base including large pharma and Ivy League institution
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
BCT
OPEN ARTICLE